Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis
This article was originally published in The Tan Sheet
Executive Summary
Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.